title: Effects of metergoline on symptoms in women with premenstrual dysphoric disorder.
abstract: OBJECTIVE
  The authors investigated the role of acute serotonergic modulation in the efficacy of selective serotonin reuptake inhibitors (SSRIs) in women with premenstrual dysphoric disorder.
  
  
  METHODS
  Patients with premenstrual dysphoric disorder (whose symptoms had remitted during treatment with fluoxetine) and a group of unmedicated healthy comparison women received the serotonin receptor antagonist metergoline as part of a double-blind, placebo-controlled crossover study.
  
  
  RESULTS
  The patients with premenstrual dysphoric disorder experienced a return of symptoms 24 hours after treatment with metergoline but not diphenhydramine (active placebo). The comparison women experienced no changes in mood.
  
  
  CONCLUSIONS
  These data support the role of altered serotonergic transmission in the efficacy of SSRI treatment for premenstrual dysphoric disorder.
authors.affiliation: National Institute of Mental Health, Bethesda, MD 20892-1277, USA.
authors.forename: Catherine A
authors.initials: CA
authors.lastname: Roca
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Schmidt
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Smith
authors.forename: Merry A
authors.initials: MA
authors.lastname: Danaceau
authors.forename: Dennis L
authors.initials: DL
authors.lastname: Murphy
authors.forename: David R
authors.initials: DR
authors.lastname: Rubinow
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects / Q000502:physiology; D003863:Depression / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology; D004155:Diphenhydramine / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008711:Metergoline; D010555:Personality Inventory; D011293:Premenstrual Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology*; D012702:Serotonin Antagonists; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D004155:Diphenhydramine; D005473:Fluoxetine; D008711:Metergoline; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017367:Selective Serotonin Reuptake Inhibitors